|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lauren P: The two histological main types
of gastric carcinoma: Diffuse and so-called intestinal-type
carcinoma. An attempt at a Histo-clinical classification. Acta
Pathol Microbiol Scand. 64:31–49. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Qiu MZ, Cai MY, Zhang DS, Wang ZQ, Wang
DS, Li YH and Xu RH: Clinicopathological characteristics and
prognostic analysis of Lauren classification in gastric
adenocarcinoma in China. J Transl Med. 11:582013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gong EJ, Lee JY, Bae SE, Park YS, Choi KD,
Song HJ, Lee GH, Jung HY, Jeong WJ, Cheon GJ, et al:
Characteristics of non-cardia gastric cancer with a high serum
anti-Helicobacter pylori IgG titer and its association with
diffuse-type histology. PLoS One. 13:e01952642018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zheng H, Takahashi H, Murai Y, Cui Z,
Nomoto K, Miwa S, Tsuneyama K and Takano Y: Pathobiological
characteristics of intestinal and diffuse-type gastric carcinoma in
Japan: An immunostaining study on the tissue microarray. J Clin
Pathol. 60:273–277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Min L, Zhao Y, Zhu S, Qiu X, Cheng R, Xing
J, Shao L, Guo S and Zhang S: Integrated analysis identifies
molecular signatures and specific prognostic factors for different
gastric cancer subtypes. Transl Oncol. 10:99–107. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:6466–6474. 2011. View Article : Google Scholar
|
|
9
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kitadai Y: Angiogenesis and
lymphangiogenesis of gastric cancer. J Oncol. 2010:4687252010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yamamoto S, Yasui W, Kitadai Y, Yokozaki
H, Haruma K, Kajiyama G and Tahara E: Expression of vascular
endothelial growth factor in human gastric carcinomas. Pathol Int.
48:499–506. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bădescu A, Georgescu CV, Vere CC, Crăiţoiu
S and Grigore D: Correlations between Her2 oncoprotein, VEGF
expression, MVD and clinicopathological parameters in gastric
cancer. Rom J Morphol Embryol. 53:997–1005. 2012.PubMed/NCBI
|
|
13
|
Tenderenda M, Rutkowski P,
Jesionek-Kupnicka D and Kubiak R: Expression of CD34 in gastric
cancer and its correlation with histology, stage, proliferation
activity, p53 expression and apoptotic index. Pathol Oncol Res.
7:129–134. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhu XR, Wang YW, Xue WJ, Wang R, Wang L,
Zhu ML and Zheng L: The VEGFR-2 protein and the VEGFR-2 rs1870377
A>T genetic polymorphism are prognostic factors for gastric
cancer. Cancer Biol Ther. 20:497–504. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lin C, Zhang Z, Xu Y, Wang R, Chen S, Gao
J, Wang D, Huang Q, Tu X and Wang L: High tumor vascular
endothelial growth factor expression is associated with poorer
clinical outcomes in resected T3 gastric adenocarcinoma. Am J Clin
Pathol. 146:278–288. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li T, Yu J, Luo X, Ren W, Zhang Y and Cao
B: VEGFR-2 as a novel predictor of survival in gastric cancer: A
systematic review and meta-analysis. Pathol Res Pract. 214:560–564.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Polkowski W, van Sandick JW, Offerhaus GJ,
ten Kate FJ, Mulder J, Obertop H and van Lanschot JJ: Prognostic
value of Laurén classification and c-erbB-2 oncogene overexpression
in adenocarcinoma of the esophagus and gastroesophageal junction.
Ann Surg Oncol. 6:290–297. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Berlth F, Bollschweiler E, Drebber U,
Hoelscher AH and Moenig S: Pathohistological classification systems
in gastric cancer: Diagnostic relevance and prognostic value. World
J Gastroenterol. 20:5679–5684. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen YC, Fang WL, Wang RF, Liu CA, Yang
MH, Lo SS, Wu CW, Li AF, Shyr YM and Huang KH: Clinicopathological
variation of Lauren classification in gastric cancer. Pathol Oncol
Res. 22:197–202. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stiekema J, Cats A, Kuijpers A, van
Coevorden F, Boot H, Jansen EP, Verheij M, Balague Ponz O,
Hauptmann M and van Sandick JW: Surgical treatment results of
intestinal and diffuse type gastric cancer. Implications for a
differentiated therapeutic approach? Eur J Surg Oncol. 39:686–693.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qiu M, Zhou Y, Zhang X, Wang Z, Wang F,
Shao J, Lu J, Jin Y, Wei X, Zhang D, et al: Lauren classification
combined with HER2 status is a better prognostic factor in Chinese
gastric cancer patients. BMC Cancer. 14:8232014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamashita K, Sakuramoto S, Katada N,
Futawatari N, Moriya H, Hirai K, Kikuchi S and Watanabe M: Diffuse
type advanced gastric cancer showing dismal prognosis is
characterized by deeper invasion and emerging peritoneal cancer
cell: The latest comparative study to intestinal advanced gastric
cancer. Hepatogastroenterology. 56:276–281. 2009.PubMed/NCBI
|
|
23
|
Yu CC, Levison DA, Dunn JA, Ward LC,
Demonakou M, Allum WH and Hallisey MT: Pathological prognostic
factors in the second British Stomach Cancer Group trial of
adjuvant therapy in resectable gastric cancer. Br J Cancer.
71:1106–1110. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rajabi M and Mousa SA: The role of
angiogenesis in cancer treatment. Biomedicines. 5(pii): E342017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cleary JM, Horick NK, McCleary NJ, Abrams
TA, Yurgelun MB, Azzoli CG, Rubinson DA, Brooks GA, Chan JA,
Blaszkowsky LS, et al: FOLFOX plus ziv-aflibercept or placebo in
first-line metastatic esophagogastric adenocarcinoma: A
double-blind, randomized, multicenter phase 2 trial. Cancer. Mar
26–2019.(Epub ahead of print). doi: 10.1002/cncr.32029. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim ST, Lee J, Lee SJ, Park SH, Jung SH,
Park YS, Lim HY, Kang WK and Park JO: Prospective phase II trial of
pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously
untreated patients with advanced gastric cancer. Oncotarget.
7:24088–24096. 2016.PubMed/NCBI
|
|
27
|
Fuchs CS, Shitara K, Di Bartolomeo M,
Lonardi S, Al-Batran SE, Van Cutsem E, Ilson DH, Alsina M, Chau I,
Lacy J, et al: Ramucirumab with cisplatin and fluoropyrimidine as
first-line therapy in patients with metastatic gastric or
junctional adenocarcinoma (RAINFALL): A double-blind, randomised,
placebo-controlled, phase 3 trial. Lancet Oncol. 20:420–435. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fontanella C, Ongaro E, Bolzonello S,
Guardascione M, Fasola G and Aprile G: Clinical advances in the
development of novel VEGFR2 inhibitors. Ann Transl Med.
2:1232014.PubMed/NCBI
|
|
29
|
Fuchs CS, Tomasek J, Yong CJ, Dumitru F,
Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry
DR, et al: Ramucirumab monotherapy for previously treated advanced
gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An
international, randomised, multicentre, placebo-controlled, phase 3
trial. Lancet. 383:31–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wilke H, Muro K, Van Cutsem E, Oh SC,
Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et
al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in
patients with previously treated advanced gastric or
gastro-oesophageal junction adenocarcinoma (RAINBOW): A
double-blind, randomised phase 3 trial. Lancet Oncol. 15:1224–1235.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Aoyama T and Yoshikawa T: Targeted
therapy: Apatinib-new third-line option for refractory gastric or
GEJ cancer. Nat Rev Clin Oncol. 13:268–270. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li J, Qin SK, Xu JM, Xiong J, Wu C, Bai Y,
Liu W, Tong J, Liu Y, Xu R, et al: Randomized, double-blind,
placebo-controlled phase III trial of apatinib in patients with
chemotherapy-refractory advanced or metastatic adenocarcinoma of
the stomach or gastroesophageal junction. J Clin Oncol.
34:1448–1454. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Roviello G, Petrioli R, Marano L, Polom K,
Marrelli D, Perrella A and Roviello F: Angiogenesis inhibitors in
gastric and gastroesophageal junction cancer. Gastric Cancer.
19:31–41. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ohtsu A, Shah MA, Van Cutsem E, Rha SY,
Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, et al:
Bevacizumab in combination with chemotherapy as first-line therapy
in advanced gastric cancer: A randomized, double-blind,
placebo-controlled phase III study. J Clin Oncol. 29:3968–3976.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Takahashi Y, Cleary KR, Mai M, Kitadai Y,
Bucana CD and Ellis LM: Significance of vessel count and vascular
endothelial growth factor and its receptor (KDR) in intestinal-type
gastric cancer. Clin Cancer Res. 2:1679–1684. 1996.PubMed/NCBI
|
|
36
|
Chen CN, Hsieh FJ, Cheng YM, Cheng WF, Su
YN, Chang KJ and Lee PH: The significance of placenta growth factor
in angiogenesis and clinical outcome of human gastric cancer.
Cancer Lett. 213:73–82. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang L, Yang M, Shan L, Qi L, Chai C, Zhou
Q, Yao K, Wu H and Sun W: The role of SPARC protein expression in
the progress of gastric cancer. Pathol Oncol Res. 18:697–702. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang X, Cao W, Mo M, Wang W, Wu H and Wang
J: VEGF and cortactin expression are independent predictors of
tumor recurrence following curative resection of gastric cancer. J
Surg Oncol. 102:325–330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lastraioli E, Boni L, Romoli MR, Crescioli
S, Taddei A, Beghelli S, Tomezzoli A, Vindigni C, Saragoni L,
Messerini L, et al: VEGF-A clinical significance in gastric
cancers: Immunohistochemical analysis of a wide Italian cohort. Eur
J Surg Oncol. 40:1291–1298. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen L, Shi Y, Yuan J, Han Y, Qin R, Wu Q,
Jia B, Wei B, Wei L, Dai G and Jiao S: HIF-1 alpha overexpression
correlates with poor overall survival and disease-free survival in
gastric cancer patients post-gastrectomy. PLoS One. 9:e906782014.
View Article : Google Scholar : PubMed/NCBI
|
